Eli Lilly and Company today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback